Content about Mallinckrodt

April 26, 2013
Mallinckrodt collects unused medications in St. Louis

Medical products manufacturer Covidien's pharmaceutical division is expanding an initiative to collect unused and unwanted medications.

ST. LOUIS — Medical products manufacturer Covidien's pharmaceutical division is expanding an initiative to collect unused and unwanted medications.

Mallinckrodt said it would expand communities' access to drug take-back collection boxes and promote safe disposal practices, installing lock boxes in three police stations around St. Louis. The company said it purchased the boxes under a collaboration with the National Association of Drug Diversion Investigators and also would provide a grant to help incinerate the medications that are collected.

February 14, 2013
Actavis can launch generic painkiller in May 2014 under settlement

Actavis and Mallinckrodt have reached a settlement concerning the former's generic version of an opioid painkiller made by the latter, Actavis said Thursday.

PARSIPPANY, N.J. — Actavis and Mallinckrodt have reached a settlement concerning the former's generic version of an opioid painkiller made by the latter, Actavis said Thursday.

The companies settled patent lawsuit regarding Actavis' generic version of Mallinckrodt's Exalgo (hydromorphone hydrochloride) extended-release tablets in the 32-mg strength. The companies settled litigation regarding the 8-mg, 12-mg and 16-mg strengths last month.

January 27, 2012
Watson, Mallinckrodt settle over generic painkiller

Watson Pharmaceuticals and Mallinckrodt have reached a settlement concerning a painkiller for which the former had sought Food and Drug Administration approval.

PARSIPPANY, N.J. — Watson Pharmaceuticals and Mallinckrodt have reached a settlement concerning a painkiller for which the former had sought Food and Drug Administration approval.

February 11, 2011
Mallinckrodt receives FDA approval for generic Duragesic

The Food and Drug Administration has approved a painkiller delivered through a skin patch made by Mallinckrodt, the generic drug maker said Friday.

ST. LOUIS — The Food and Drug Administration has approved a painkiller delivered through a skin patch made by Mallinckrodt, the generic drug maker said Friday.

Mallinckrodt, part of Covidien, said the FDA approved its fentanyl transdermal system patch.

The patch is a generic version of Johnson & Johnson’s Duragesic. The drug, an opioid and Class II controlled substance, is used for managing persistent, moderate-to-severe pain that requires continuous opioid administration.

December 15, 2010
Watson confirms patent challenge over generic Exalgo

Drug maker Watson Pharmaceuticals said it has filed a regulatory approval application for a generic painkiller, challenging the patent that covers the branded version.

MORRISTOWN, N.J. — Drug maker Watson Pharmaceuticals said it has filed a regulatory approval application for a generic painkiller, challenging the patent that covers the branded version.

Watson announced Tuesday that it had filed an application with the Food and Drug Administration seeking approval for hydromorphone hydrochloride extended-release tablets in the 8-mg, 12-mg and 16-mg strengths. The drug is a generic version of Mallinckrodt’s Exalgo.